<i>Diabetes Care</i> to Date: “The Hits Just Keep on Coming!”

Cefalu, William T.

doi:10.2337/dc13-0906

Cited by 2 publications

(2 citation statements)

References 34 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In the USA, between 1998 and 2017, the total expenses with DM had a fourfold increase up to 327 billion USD [10][11][12][13]. In Canada, the DM expenses increased with 0.5 billion USD, from 1993 to 1998.…”

Section: Introductionmentioning

confidence: 99%

An Exploratory Research of 18 Years on the Economic Burden of Diabetes for the Romanian National Health Insurance System

Morgovan

Cosma

Văleanu

et al. 2020

IJERPH

View full text Add to dashboard Cite

The prevalence of diabetes mellitus (DM) rises constantly each year worldwide. Because of that, the funds allocated for the DM treatment have increased over time. Regarding the number of DM cases, Romania is among the top ten countries in Europe. Based on the National Diabetes Programme (NDP), antidiabetic drugs and other expenditures (Self-monitoring blood glucose (SMBG) test, HbA1c, insulin pumps/insulin pumps supplies) are free of charge. This programme has undergone many changes in drugs supply, in the last two decades: re-organizing the NDP, authorization of new molecules with high prices (e.g., SGLT-2 inhibitors, etc.) or new devices (e.g., insulin pumps, etc.) The main purpose of this study is to identify and analyse the impact of the DM costs on the Romanian health budget and to highlight the evolution of these costs. A retrospective longitudinal research on the official data regarding the DM costs from 2000 to 2017 was performed. The DM funds (DMF) were adjusted with the inflation rate. In this period, the average share of DMF in the total funds allocated for health programmes was 21.3 ± 3.4%, and DMF average growth rate was 25.4% (r = 0.488, p = 0.047). On the other hand, the DMF increased more than 14 times, in spite of the patients’ number having increased only about 2.5 times. Referring to the structure of DMF, the mean value of the antidiabetic drugs cost was of 96,045 ± 67,889 thousand EUR while for other expenditures it was of 11,530 ± 7922 thousand EUR (r = 0.945, p < 0.001). Between 2008 and 2017, the total DMF was 181,252 ± 74,278 thousand EUR/year. Moreover, the average patients’ number was 667,384 ± 94,938 (r = 0.73, p = 0.016), and the cost of treatment was 215 ± 36 EUR/patient/year. Even if the cost is rising, the correct and optimal treatment is a main condition for the diabetic patient’s health and for the prevention of its complications, which have multiple socio-economic repercussions.

show abstract

Section: Introductionmentioning

confidence: 99%

An Exploratory Research of 18 Years on the Economic Burden of Diabetes for the Romanian National Health Insurance System

Morgovan

Cosma

Văleanu

et al. 2020

IJERPH

View full text Add to dashboard Cite

show abstract

“…For example, when we provided our update on the journal for July 2013, we titled it “The Hits Just Keep on Coming!” (1). It was stated at the time: “To be honest, I would be thrilled if, in January 2014, I can simply state we’ve had more of the same!” Honestly, this is far from the truth.…”

mentioning

confidence: 99%